Workflow
Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients
LLYLilly(LLY) Prnewswire·2025-02-25 11:45

Core Points - Eli Lilly and Company has launched new 7.5 mg and 10 mg Zepbound single-dose vials priced at 499permonththroughtheZepboundSelfPayJourneyProgram,whilealsoreducingthepricesofthe2.5mgand5mgvials[1][6]−TheZepboundSelfPayJourneyProgramaimstoimproveaffordabilityforself−paypatientswithobesity,providingadditionalvialoptionsandtransparentpricingbyeliminatingthird−partysupplychainentities[2][6]−ZepboundisthefirstdualGIPandGLP−1receptoragonistobesitymedication,indicatedforadultswithobesityoroverweightwithweight−relatedmedicalissues,andisFDA−approvedfortreatingmoderate−to−severeobstructivesleepapnea[4][16]PricingandAvailability−Thepriceforthe2.5mgdosehasbeenloweredto499 per month through the Zepbound Self Pay Journey Program, while also reducing the prices of the 2.5 mg and 5 mg vials [1][6] - The Zepbound Self Pay Journey Program aims to improve affordability for self-pay patients with obesity, providing additional vial options and transparent pricing by eliminating third-party supply chain entities [2][6] - Zepbound is the first dual GIP and GLP-1 receptor agonist obesity medication, indicated for adults with obesity or overweight with weight-related medical issues, and is FDA-approved for treating moderate-to-severe obstructive sleep apnea [4][16] Pricing and Availability - The price for the 2.5 mg dose has been lowered to 349 per month, while the 5 mg dose remains at 499permonth[6]−Thenewpricingforthe7.5mgand10mgdosesisapplicableforthefirstfillandrefillswithin45days;otherwise,thepricesrevertto499 per month [6] - The new pricing for the 7.5 mg and 10 mg doses is applicable for the first fill and refills within 45 days; otherwise, the prices revert to 599 and $699 respectively [6][32] Company Commitment - Eli Lilly is committed to addressing the lack of comprehensive care and coverage for obesity treatment, working with various stakeholders to improve access and affordability for patients [2][4] - The company emphasizes the need for systemic changes in healthcare coverage for obesity, as recognized by major medical organizations [2]